TransMed7

TransMed7, LLC is a United States-based developer of novel medical devices, headquartered in Phoenix, Arizona. The company positions itself around a single guiding principle — that patients always come first — and describes its mission as serving as many patients in need as possible with the safest and most effective technology it can offer. Rather than selling a single instrument, TransMed7 organizes its work into device platforms: each platform is built on one core concept and then expanded into individual device models that address the differing needs of surgeons, interventional radiologists and their patients. The technical foundation of the company is its patented Zero5 technology, an FDA-cleared rotating-beak design for forward-coring biopsy. TransMed7 markets Zero5 as delivering five critical advantages over traditional side-cutting devices: zero dead space, zero collateral tissue displacement, zero limitations on sample length, zero restrictions on tissue density, and zero sample structure distortion. The company frames this as "the new frontier of forward-coring biopsy devices," using the hummingbird — described as nature's most skillful surgeon — as its accuracy metaphor. From that base, TransMed7 has generated a portfolio of named platforms. SpeedBird applies Zero5 to handheld, ultrasound-guided soft tissue biopsy for breast health. Concorde applies it to stereotactic, 2D/3D tomosynthesis or ultrasound-guided breast biopsy, supporting forward or combined forward-and-side coring with a familiar "around the clock" sampling procedure and no console required. Cardinal addresses true Fine Needle Core Biopsy (FNCB) for lymph node, thyroid, liver, pancreas and kidney biopsies. Heron is the SIMC platform for prostate, liver and kidney procedures, including the Heron XP automatic core sampling device and the Heron RO robotic device with a remote control unit, active pain management and potential simultaneous biopsy and debulking for BPH. Additional platforms include Corsair for cardiovascular intervention and advanced atherectomy, Martinet for whole-lesion excisional biopsy, Phoenix for flexible and steerable microcatheters used in endoscopic and robotic endoscopic procedures, and Cygnet for bone marrow biopsy and stem cell harvesting. Common threads across the portfolio are single insertion, multiple collection (SIMC), minimally traumatic action, precise targeting to avoid collateral damage to sensitive vascular, nerve and urethral structures, ease of use, consistent and reproducible high-quality samples, and cost effectiveness. TransMed7 presents these attributes as a way to encourage earlier diagnosis by making procedures gentler and more tolerable for patients. The company operates as a private limited liability company and, per public records, is associated with Phoenix, United States.

TransMed7, LLC is a privately held United States medical device developer associated with Phoenix, Arizona. Public records describe it simply as a company in Phoenix, United States, and its own materials present it as a developer of novel medical devices whose guiding principle is that patients always come first. The company's history is best understood through the evolution of its technology platform rather than through a long chronology of corporate events. TransMed7 built its identity around Zero5, a patented and FDA-cleared rotating-beak design for forward-coring biopsy. The company describes Zero5 as a revolution in biopsy procedures, offering five critical advantages over traditional side-cutting devices: zero dead space, zero collateral tissue displacement, zero limitations on sample length, zero restrictions on tissue density, and zero sample structure distortion. This technology is the common core from which every TransMed7 product platform is derived. From that core, TransMed7 developed a family of named platforms, each aimed at a specific clinical field. SpeedBird was created as the application of Zero5 to handheld, ultrasound-guided soft tissue biopsy for breast health, emphasizing forward coring, minimal trauma, single insertion with multiple collection (SIMC), ease of use, consistent and reproducible high-quality samples, and cost effectiveness. Concorde extended Zero5 to stereotactic, 2D/3D tomosynthesis or ultrasound-guided breast biopsy, supporting forward or combined forward-and-side coring, a familiar "around the clock" sampling procedure, unlimited access, the ability to sample multiple targets, no console requirement, concordance for high-quality samples, gentle action for patient comfort, SIMC, and minimal set-up and waste. Cardinal was developed for true Fine Needle Core Biopsy (FNCB) in lymph node, thyroid, liver, pancreas and kidney biopsies. The Heron platform represents a further expansion into prostate, liver and kidney procedures. Heron devices were designed to obtain biopsy samples from small or fragile tissues, using SIMC to reduce tissue damage and procedure times while controlling pain and limiting damage to sensitive nearby structures. The platform includes the Heron XP automatic core sampling device and the Heron RO robotic device, which pairs Zero5 technology in 12–18 gauge core needle options with active pain management via an open central lumen and anesthetic injection port, precise targeting to avoid collateral damage to vascular and nerve bundles and the urethra in the prostate, and the potential for simultaneous biopsy and debulking to reduce BPH symptoms. A remote control unit (RCU) supports future robotic applications for prostate biopsy and BPH symptom relief. Beyond these, TransMed7's product page lists additional platforms under development or being deployed: Corsair, described as a new Zero5-based cardiovascular intervention baseline for advanced atherectomy procedures; Martinet, for whole lesion excisional biopsy leaving a near-spherical cavity for post-procedure therapeutic treatment options; Phoenix, Zero5-based flexible and steerable microcatheters for endoscopic biopsy and robotic endoscopic procedures; and Cygnet, rugged Zero5 technology for gentle bone marrow biopsy, stem cell harvesting and rapid hydration. The company states that further information for many of these new platform technologies is available through its website. TransMed7's stated philosophy is that everything — its business structure, technologies, partnerships, activities and people — works together to serve patients around the globe, and it invites partners and collaborators to join in that effort. The company operates as a private limited liability company and does not appear to be publicly listed.

• TransMed7 develops and patents Zero5, an FDA-cleared rotating-beak forward-coring biopsy technology.

• SpeedBird platform introduced for handheld, ultrasound-guided breast biopsy.

• Concorde platform introduced for stereotactic / 2D-3D tomosynthesis and ultrasound breast biopsy.

• Cardinal platform introduced for true Fine Needle Core Biopsy (FNCB) of lymph node, thyroid, liver, pancreas and kidney.

• Heron SIMC platform introduced for prostate, liver and kidney procedures, including Heron XP and Heron RO robotic device.

• Additional platforms announced or under development: Corsair, Martinet, Phoenix and Cygnet.

Developer of novel, minimally invasive medical device platforms built on patented Zero5 forward-coring technology, positioned around patient-first design, single-insertion multiple-collection (SIMC) procedures, precision, control and cost effectiveness.

• Zero5

  Patented and FDA-cleared rotating-beak forward-coring biopsy technology with five claimed advantages: zero dead space, zero collateral tissue displacement, zero limitations on sample length, zero restrictions on tissue density, zero sample structure distortion.

• SpeedBird

  Zero5-based handheld, ultrasound-guided soft tissue biopsy platform for breast health; forward coring, minimally traumatic, single insertion multiple collection (SIMC), ease of use, consistent high-quality samples, cost effective.

• Concorde

  Zero5-based platform for stereotactic / 2D-3D tomosynthesis or ultrasound-guided breast biopsy; forward or combined forward-and-side coring, familiar 'around the clock' procedure, unlimited access, multiple targets, no console needed, gentle action.

• Cardinal

  Zero5-based platform for true Fine Needle Core Biopsy (FNCB) of lymph node, thyroid, liver, pancreas and kidney.

• Heron

  SIMC biopsy platform for prostate, liver and kidney minimally invasive procedures; includes Heron XP automatic core sampling device and Heron RO robotic device with remote control unit, active pain management and potential simultaneous biopsy and BPH debulking.

• Corsair

  New Zero5-based cardiovascular intervention baseline for advanced atherectomy procedures.

• Martinet

  Whole lesion excisional biopsy device leaving a near-spherical cavity for post-procedure therapeutic treatment options.

• Phoenix

  Zero5-based flexible and steerable microcatheters for endoscopic biopsy and robotic endoscopic procedures.

• Cygnet

  Rugged Zero5 technology for gentle bone marrow biopsy, stem cell harvesting and rapid hydration.

1. 1TransMed7, LLC – A World Of Challenges. One Solution.transmed7.com
2. 2About – TransMed7, LLCtransmed7.com
3. 3Products – TransMed7, LLCtransmed7.com
4. 4Heron – TransMed7, LLCtransmed7.com
5. 5TransMed7 (United States) – Wikidatawikidata.org